177 related articles for article (PubMed ID: 25823922)
1. Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.
Colamonici M; Blyth G; Saleiro D; Szilard A; Bliss-Moreau M; Giles FJ; Altman JK; Beauchamp EM; Platanias LC
Oncotarget; 2015 Apr; 6(10):8062-70. PubMed ID: 25823922
[TBL] [Abstract][Full Text] [Related]
2. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract][Full Text] [Related]
3. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma.
Eckerdt F; Clymer J; Bell JB; Beauchamp EM; Blyth GT; Goldman S; Platanias LC
Sci Rep; 2019 Sep; 9(1):12822. PubMed ID: 31492956
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
6. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.
Deng L; Jiang L; Lin XH; Tseng KF; Liu Y; Zhang X; Dong RH; Lu ZG; Wang XJ
Acta Pharmacol Sin; 2017 Mar; 38(3):382-391. PubMed ID: 28042875
[TBL] [Abstract][Full Text] [Related]
7. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.
Zhang W; Ruvolo VR; Gao C; Zhou L; Bornmann W; Tsao T; Schober WD; Smith P; Guichard S; Konopleva M; Andreeff M
Mol Cancer Ther; 2014 Jul; 13(7):1848-59. PubMed ID: 24739393
[TBL] [Abstract][Full Text] [Related]
9. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
11. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S
Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658
[TBL] [Abstract][Full Text] [Related]
12. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.
Su Y; Li X; Ma J; Zhao J; Liu S; Wang G; Edwards H; Taub JW; Lin H; Ge Y
Biochem Pharmacol; 2018 Feb; 148():13-26. PubMed ID: 29208365
[TBL] [Abstract][Full Text] [Related]
13. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
14. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA
Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954
[TBL] [Abstract][Full Text] [Related]
15. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.
Vachhani P; Bose P; Rahmani M; Grant S
Physiol Genomics; 2014 Jul; 46(13):448-56. PubMed ID: 24824212
[TBL] [Abstract][Full Text] [Related]
16. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
17. Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.
Carneiro BA; Kaplan JB; Altman JK; Giles FJ; Platanias LC
Cancer Biol Ther; 2015; 16(5):648-56. PubMed ID: 25801978
[TBL] [Abstract][Full Text] [Related]
18. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
Herschbein L; Liesveld JL
Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
[TBL] [Abstract][Full Text] [Related]
19. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
[TBL] [Abstract][Full Text] [Related]
20. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
Hong Z; Xiao M; Yang Y; Han Z; Cao Y; Li C; Wu Y; Gong Q; Zhou X; Xu D; Meng L; Ma D; Zhou J
Carcinogenesis; 2011 Oct; 32(10):1550-8. PubMed ID: 21803735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]